- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Advanced, metastatic or recurrent endometrial cancer
- Meeting Date: November 2024
- Public Summary Document (PSD) November 2024 PBAC Meeting - (PDF 1.6MB)
- Public Summary Document (PSD) November 2024 PBAC Meeting - (Word 1.3MB)
Durvalumab olaparib – November 2024
Durvalumab-and-olaparib: Solution concentrate for i.v. infusion durvalumab 120 mg in 2.4 mL, 500 mg in 10 mL, Imfinzi® and olaparib Tablet 100 mg, Tablet 150 mg, Lynparza®
Last updated
30 May 2025
